TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05031481
Drug: Venus 20 + 0,064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venus vaginal cream 20 + 0,064, single-dose.
Study: NCT05497635
Drug: STSA-1002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05497635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05529940
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Study: NCT05357547
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-sucrose tablets in opaque capsule
Study: NCT04896385
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT05129891
Drug: NNC0385-0434 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet given orally
Study: NCT05045833
Drug: SYN-020 Delayed Release Capsule
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration (by mouth)
Study: NCT05561374
Drug: Low-dose OKN-007, BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
Study: NCT05561374
Drug: Low-dose OKN-007, TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
Study: NCT05561374
Drug: Mid-dose OKN-007, TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
Study: NCT05561374
Drug: High-dose OKN-007, TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Study: NCT06448585
Drug: Specific immunotherapy (SIT) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
Study: NCT05895136
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT will be considered non-study medication and is not specified in the protocol.
Study: NCT05476679
Drug: RZL-012+Medrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
Study: NCT05476679
Drug: RZL-012+Celecoxib+Zyrtec
Normalized name: ZyrTEC
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
Study: NCT05476679
Drug: RZL-012+facial and neck wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Facial Band
Study: NCT06328439
Drug: ANS014004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 7.5mg; 30mg QD/BID Oral
Study: NCT05797168
Drug: AZD5335
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Antibody-drug conjugate
Study: NCT04950127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo.
Study: NCT05688280
Drug: 1.0% IP-001 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
Study: NCT04733144
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
Study: NCT04948697
Drug: BAT1706
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
Study: NCT05879718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous infusion)
Study: NCT06543043
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06424834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once orally daily.
Study: NCT06355427
Drug: [18F]F-FAPI PET-CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Study: NCT04441034
Drug: Anti-convulsant medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-convulsants are very commonly used to treat patients with chronic pain.
Study: NCT04441034
Drug: Anti-depressant medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-depressants are very commonly used to treat patients with chronic pain.
Study: NCT06608472
Drug: Benicar HCT ® Tablets 40 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
Study: NCT06617832
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo pill (100 mg) looking like the active drug
Study: NCT06682169
Drug: Rovadicitinib
Normalized name: Rovadicitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
Study: NCT06682169
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
Study: NCT06109311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06693960
Drug: Drug cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
Study: NCT06710431
Drug: AFA-281
Normalized name: ADAPTER,ASPIRA/FLUSH,LUER URESIL AFA-LL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFA-281
Study: NCT06709807
Drug: CKD-378 25/1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06708897
Drug: ZE 50-0134
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules QD
Study: NCT05442190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
Study: NCT05502341
Drug: BIC/LEN FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT05502341
Drug: Stable Baseline Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk
Study: NCT05957367
Drug: DCC-3116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet Formulation
Study: NCT06199037
Drug: SHR-1707 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
Study: NCT04797000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Study: NCT05296681
Drug: NBT-NM108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive irinotecan-based chemotherapy per standard of care.
Study: NCT06431373
Drug: Placebo PO QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO QD
Study: NCT04713657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
Study: NCT05011305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Study: NCT06391905
Drug: PCSK9 inhibitor in combination with standard advanced first-line regimen group
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
Study: NCT05443061
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
Study: NCT05817526
Drug: BMAC/ collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
Study: NCT06143553
Drug: Capecitabine Tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
Study: NCT06092606
Drug: Control group:DH001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: DH001 placebo (8 tablets)
Study: NCT06092606
Drug: Trial group: DH001 low-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)
Study: NCT06092606
Drug: Trial group: DH001 high-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: DH001 400mg (8 tablets).
Study: NCT06365216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a week, for 4 weeks
Study: NCT05816733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
Study: NCT04912011
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Study: NCT06083935
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon; two film coated tablets 500 mg daily
Study: NCT04946461
Drug: Dexamfetamine Sulfate 5 Mg Oral Tablet
Normalized name: Dexamfetamine sulfate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
Study: NCT05712876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05128929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet placebo (inactive ingredients) two times a day.
Study: NCT05255653
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Study: NCT06492005
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
Study: NCT05014490
Drug: Exib 120 mg etoricoxib film-coated tablets
Normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
Study: NCT05014490
Drug: Arcoxia® 120 mg etoricoxib film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
Study: NCT05559554
Drug: AK104 (after the change)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
Study: NCT05219500
Drug: FPI-2265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
Study: NCT05693844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
Study: NCT05947760
Drug: IV Magnesium Sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV Magnesium Sulfate intraoperatively.
Study: NCT05798611
Drug: ART0380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized patients will orally receive ART0380.
Study: NCT05672199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT06648681
Drug: Control (placebo) group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge, whichever occurs first. The initiation criteria and the procedure if sleep is not initiated within 1 hour is the same as the intervention arm .
Study: NCT05387954
Drug: Oral Anticoagulant, Direct-Acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
Study: NCT05494320
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Study: NCT05387954
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Study: NCT04240054
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
Study: NCT06004687
Drug: acetaminophen mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetaminophen was administered 30 minutes before anesthesia
Study: NCT06004687
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen was administered 30 minutes before anesthesia
Study: NCT04811573
Drug: EU-sourced Otezla®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product
Study: NCT04811573
Drug: US-sourced Otezla®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product 1
Study: NCT04811573
Drug: Japan-sourced Otezla®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product 2
Study: NCT06217302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablets identical to sotagliflozin tablets
Study: NCT05569811
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
Study: NCT05718817
Drug: XEN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 capsules
Study: NCT05590221
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT05718544
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Study: NCT05320302
Drug: [11C]-Lu AF88370
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET ligand in a single intravenous bolus injection
Study: NCT05633615
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06184399
Drug: Placebo IVM ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ivermectin ODT
Study: NCT06460038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT04581759
Drug: foundational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
Study: NCT05056844
Drug: Iodinated Contrast Agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given iodine-based contrast agent IV
Study: NCT06798896
Drug: SPN-817
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Study: NCT06798896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, bid
Study: NCT06027086
Drug: DRP-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration.
Study: NCT05834413
Drug: chemotherapy plus TCM 1&ICIs plusTCM2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Study: NCT05834413
Drug: chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Study: NCT05889572
Drug: MaaT033
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
Study: NCT04710056
Drug: REGN4461
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05484375
Drug: Capecitabine plus toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
Study: NCT05347095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously/IV infusion.
Study: NCT06403670
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
Study: NCT05627648
Drug: KP-100LI
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracordal injection, 20 mcg once per week, 3 weeks
Study: NCT05627648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracordal injection, once per week, 3 weeks
Study: NCT04316546
Drug: MK-7075 (miransertib)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.